Summary of Sharps Technology Conference Call Company Overview - **Company**: Sharps Technology (STSS) - **Industry**: Specialized drug delivery systems, focusing on safety syringes and prefilled syringes [4][5] Key Points and Arguments - **IPO and Funding**: Sharps Technology went public in April 2022, raising approximately $16 million to acquire a facility in Hungary and commercialize its products [5] - **Acquisition of Safeguard Medical Facility**: The acquisition of a syringe operation in Hungary provided Sharps with its own intellectual property and advanced technology [5][6] - **Sales Agreements**: - A significant $50 million revenue agreement for specialized Sologuard products with a US contract filler in Texas was secured, marking a transformational opportunity for the business [7][20] - Ongoing negotiations for prefilled syringes in South Carolina, although facing some challenges [6][7] - **Manufacturing Plans**: - Plans to scale up manufacturing capabilities in Hungary and South Carolina, with new equipment expected to be operational by Q4 [8][10][22] - The facility in Hungary is fully operational and capable of scaling up to 100,000 square feet, supporting both smart safety syringe technology and prefilled syringe technology [9][10][15] - **Product Development**: - Focus on SecurGuard and Sologuard products, which include advanced safety features and low waste capabilities [11][19] - Prefilled syringes made from copolymer materials are positioned as a high-growth area, offering advantages over traditional glass syringes [12][13][27] - **Market Trends**: - The syringe market is experiencing significant growth, with a shift from glass vials to prefilled syringes, driven by pharmaceutical companies' investments [24][25] - The prefilled syringe market is expected to overtake disposable syringes in the long term [25] - **Competitive Advantage**: - Sharps Technology's products feature low waste technology, which minimizes drug loss during administration, and reuse prevention capabilities, addressing safety concerns [50][51] - The company aims to carve out a niche in the specialty syringe market by leveraging relationships with healthcare providers [42][43] Additional Important Information - **Financial Position**: The company reported a strong cash position of over $11 million with no debt, and a market cap of $6 million [37] - **Future Plans**: Sharps is committed to expanding its prefilled syringe capabilities, with potential announcements expected by the end of the year [36] - **Industry Context**: Competitors like Eli Lilly and Schott are making significant investments in drug filling capabilities, indicating a growing demand for specialized packaging solutions [29][30] This summary encapsulates the key insights from the Sharps Technology conference call, highlighting the company's strategic direction, market opportunities, and competitive positioning within the specialized drug delivery industry.

Core Viewpoint - Sharps Technology, Inc. is transitioning to revenue-generating operations with its first commercial deliveries of smart safety syringe products, marking a significant milestone for the company [2][4]. Company Overview - Sharps Technology is a medical device and pharmaceutical packaging company that specializes in patented smart safety syringe products designed for the healthcare industry [4]. - The company focuses on ultra-low waste capabilities and incorporates both passive and active safety features in its syringe technologies [4]. - Sharps has a manufacturing facility in Hungary that has undergone significant upgrades to support high-volume production [2][4]. Recent Developments - The company has commenced shipments under three customer orders linked to previously announced purchase agreements, representing its first commercial deliveries [2]. - CEO Robert Hayes will present at the Life Sciences Virtual Investor Forum on June 12, 2025, providing an opportunity for real-time investor engagement [1][6]. Event Details - The Life Sciences Virtual Investor Forum will be an interactive online event where investors can ask questions in real-time [3]. - An archived webcast will be available for those unable to attend the live event [3].

Company Overview - Sharps Technology, Inc. is an innovative medical device and pharmaceutical packaging company that offers patented smart safety syringe products to the healthcare industry [6] - The company focuses on ultra-low waste capabilities and incorporates both passive and active safety features in its syringe technologies [6] - Sharps has a manufacturing facility in Hungary that has undergone significant upgrades to support high-volume production [2][6] Recent Developments - Sharps has commenced shipments under three customer orders tied to previously announced purchase agreements, marking its first commercial deliveries and transition to revenue-generating operations [2] - The company will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET, providing an opportunity for investors to gain insights into its operations and future prospects [1][8] Investor Engagement - The Investor Summit is tailored for investors focused on small- and micro-cap stocks, offering insights from management teams of emerging companies [3][4] - Registration for the Investor Summit is available for free, allowing investors to participate and learn more about Sharps and other companies [5]

Core Viewpoint - Sharps Technology, Inc. has initiated shipments for its SecureGard and SoloGard product lines, marking its transition to a commercial-stage company and the beginning of revenue generation [2][5]. Group 1: Shipments and Orders - The company has commenced shipments under a previously announced $50 million supply agreement for SoloGard, with the first commercial order valued at $400,000 [2][3]. - SecureGard smart safety syringes were delivered to a Hungarian vaccine provider following a $100,000 purchase order, contributing to total purchase commitments of approximately $500,000 [5]. - An additional shipment of 200,000 units of 1ml low-dead space syringes has been initiated for a Swiss-based provider, representing the first tranche of a 1-million-unit order [6]. Group 2: Product Features and Manufacturing - SoloGard features an ultra-low waste design, standard luer lock compatibility, and re-use prevention technology, manufactured at the company's upgraded facility in Hungary [3][4]. - SecureGard includes an integrated active recessed safety system, also designed for ultra-low waste and re-use prevention [5]. - The manufacturing of SoloGard is supported by advanced molding and automation technologies, enabling the company to meet anticipated demand increases by the second half of 2025 [4]. Group 3: Market Performance - STSS stock has seen a significant increase of 60.60%, trading at $6.01 at the time of publication [6].

Core Insights - Sharps Technology, Inc. has initiated shipments of its SecureGard™ and SoloGard™ smart safety syringes, marking its transition to a commercial-stage, revenue-generating company [1][5] Group 1: Product Shipments and Agreements - The first commercial order of SoloGard was shipped under a $50 million supply agreement with a U.S.-based leader in IV flushing solutions, including customized 10mL SoloGard syringes [2] - The initial purchase order for SoloGard is valued at $400,000 and is part of a five-year contract to supply up to 500 million syringes [2] - A separate shipment of SecureGard smart safety syringes was delivered to a Hungarian vaccine provider under a $100,000 purchase order, reflecting growing global demand [3] - Additionally, 200,000 units of 1mL low dead space syringes were shipped to a Swiss provider for use in specialized injection pens, representing the first tranche of a 1-million-unit order [4] Group 2: Manufacturing and Operational Milestones - The manufacturing of SoloGard is supported by advanced molding and automation technologies, enabling Sharps to meet anticipated demand increases in the second half of 2025 [2] - Significant upgrades to the Hungary-based facility have been made to support high-volume, high-precision production, enhancing production capacity and quality [5] - The company is building inventory and expanding capacity to support current and future purchase commitments under long-term strategic agreements [5] Group 3: Company Vision and Future Outlook - The CEO of Sharps Technology emphasized that these initial shipments represent a key operational milestone and validate years of R&D and strategic planning [5] - The company aims to deepen relationships with partners and drive additional growth in the upcoming quarters [6]

Summary of Sharps Technology (STSS) Conference Call - May 22, 2025 Company Overview - **Company**: Sharps Technology (STSS) - **Industry**: Medical Devices, specifically focusing on syringe technology Key Points and Arguments 1. **Sales Agreement**: The company executed a $50,000,000 sales agreement with a large US filler for 10 ml syringes, signed in July 2024, which will utilize most of the capacity of their European facility [1][2] 2. **Expansion Potential**: The agreement has the potential to expand production by an additional 250 million units, supported by a financial raise with Aegis to enhance equipment and technology [2] 3. **Facility Details**: The European facility is debt-free and specializes in smart safety syringe technology, with plans for scalability and expansion to meet contract demands [2][3] 4. **US Manufacturing Facility**: The company is actively seeking a US manufacturing facility, particularly in South Carolina, to produce prefillable syringes using advanced copolymer technology, which is seen as a significant growth area in drug delivery [3][4] 5. **Product Overview**: Current products include SecurGuard and Solarguard syringes, which feature low waste technology and passive safety mechanisms [4][5] 6. **Market Growth**: The prefilled syringe market is rapidly growing, with significant investments from healthcare companies, indicating a strong opportunity for organic growth and partnerships [8][9] 7. **Regulatory Challenges**: The medical device industry has a lengthy lifecycle from concept to commercialization, requiring extensive regulatory approvals [14][15] 8. **Revenue Generation**: The company anticipates early revenue generation in Q2 2025 from initial shipments to the US customer, with a commitment for ongoing orders as production scales [7][28] 9. **Debt Status**: The company is currently debt-free after using part of a $20,000,000 financing to pay down previous loans [25] 10. **Future Projections**: Plans to be cash flow positive by next year, with strategic projects aimed at bringing prefillable syringes to market [35] Additional Important Information 1. **Reverse Stock Split**: A reverse stock split was executed to comply with Nasdaq requirements, which is expected to enhance long-term value for investors [21][31] 2. **Warrant Structure**: Most warrants have been eliminated, improving the company's financial position [33] 3. **Market Demand**: There is increasing demand for prefilled syringes, with copolymer technology offering advantages over traditional glass syringes, such as reduced breakage and improved manufacturing processes [40][42] 4. **Production Capabilities**: The Hungarian facility is positioned to support both current and future production demands, with potential for expansion and flexibility in product offerings [50][52] This summary encapsulates the key insights from the conference call, highlighting Sharps Technology's strategic initiatives, market opportunities, and operational capabilities within the medical device industry.

Core Insights - Sharps Technology, Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share and the minimum stockholders' equity requirement of $2.5 million, allowing its common stock to continue being listed and traded on Nasdaq [1][2]. Company Overview - Sharps Technology is an innovative medical device and pharmaceutical packaging company that offers patented smart-safety syringe products, focusing on ultra-low waste capabilities and incorporating both passive and active safety features [4]. - The company has a manufacturing facility located in Hungary and is transitioning from the pre-revenue qualification phase to revenue-generating commercial operations [3][4]. Recent Developments - The company has received its first purchase orders for its products, SecureGard and SoloGard, and will soon begin shipping from its Hungary-based manufacturing facility [3]. - The CEO of Sharps Technology emphasized the importance of maintaining the Nasdaq listing and expressed optimism about the company's transition to commercial operations, indicating a pivotal moment in its history [3].

Company Overview - Sharps Technology, Inc. is an innovative medical device and pharmaceutical packaging company that offers patented, best-in-class smart-safety syringe products to the healthcare industry [2] - The company's product lines focus on ultra-low waste capabilities and incorporate both passive and active safety features in syringe technologies [2] - Sharps Technology also provides products designed with specialized copolymer technology to support the prefillable syringe market segment [2] - The company operates a manufacturing facility located in Hungary [2] Presentation Details - Robert Hayes, the CEO of Sharps Technology, is scheduled to present at the Aegis Capital Corp. 2025 Virtual Conference on May 22, 2025, at 1:00 p.m. ET [1][4] - The presentation will be webcasted, allowing broader access to stakeholders and interested parties [1][4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of registrant as specified in its charter) of incorporation or organization Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-41355 Sharps Technology, Inc. (I.R.S. Employer Identification No.) 105 Maxess Road, Melville, ...

Core Insights - Sharps Technology, Inc. has received a total of approximately $500,000 in purchase orders for Q2, marking a significant transition to a revenue-producing stage for the company [1][2] - The recent orders include a $100,000 purchase from a Hungarian vaccine provider and a $400,000 order for the SoloGard™ product, part of a broader $50 million agreement with a U.S. company [1][2] - The company has also received an initial qualification order for the DisGard™ Sharps Recovery System, which is designed for safe disposal of surgical sharps [2] Company Overview - Sharps Technology specializes in innovative medical devices and pharmaceutical packaging, focusing on patented smart-safety syringe products [6] - The company emphasizes ultra-low waste capabilities and incorporates both passive and active safety features in its syringe technologies [6] - Manufacturing is conducted at a state-of-the-art facility in Hungary, which is equipped to meet ongoing and future demand [3] Product Details - The SecureGard Retractable Safety Syringe is a key product, designed to minimize accidental reuse and needle stick injuries through a manual retraction feature [4] - The product line includes low dead space syringes that reduce drug wastage and are available in 1ml, 3ml, and 5ml capacities [7] - The company aims to scale production and fulfillment to support its expanding pipeline of purchase agreements [3]